Twitter Facebook LinkedIn YouTube

Filament Health, a clinical–stage natural psychedelic drug development company, announced a second agreement to supply its botanical psilocybin drug candidate, PEX010, to the Centre for Addiction and Mental Health.

Video Platform Video Management Video Solutions Video Player

Filament Health (NEO:FH) (OTCQB:FLHLF) (FSE:7QS), a clinical–stage natural psychedelic drug development company, announced a second agreement to supply its botanical psilocybin drug candidate, PEX010, to the Centre for Addiction and Mental Health. The Centre for Addiction and Mental Health (CAMH), Canada's largest mental health teaching hospital and one of the world's leading research centres, will study the effects of psilocybin for the treatment of amnestic mild cognitive impairment (aMCI) in a Health Canada-approved clinical trial.

Additional Information:

Company: Filament Health Corp
Website: www.filament.health
Stock Symbol: NEO:FH
Date Published: Feb 14, 2023
Transcript: Available

Video Transcript:

Filament Health Corp. (NEO:FH) (OTCQB:FLHLF) (FSE:7QS), a clinical–stage natural psychedelic drug development company, announced a second agreement to supply its botanical psilocybin drug candidate, PEX010, to the Centre for Addiction and Mental Health.

The Centre for Addiction and Mental Health (CAMH), Canada's largest mental health teaching hospital and one of the world's leading research centres, will study the effects of psilocybin for the treatment of amnestic mild cognitive impairment (aMCI) in a Health Canada-approved clinical trial.

Dr. Philip Gerretsen, co-lead investigator for the CAMH trial, stated: "Current treatments for aMCI are ineffective, and the examination of novel interventions is required to help prevent progression to Alzheimer's Dementia. This trial will examine if psilocybin can increase participants' synaptic density, which has previously been shown to occur in animal studies. We are very grateful to Filament Health for their donation of safe, high quality psilocybin which is crucial to the trial design."

Patients with aMCI are at higher risk of having Alzheimer's Disease and developing dementia.

No effective treatment currently exists to prevent progression from aMCI to AD, and psilocybin represents a novel approach to promote synaptogenesis in the early stages which may counter neurodegeneration.

Benjamin Lightburn, CEO and Co-Founder of Filament Health, added: "We're proud to continue building our relationship with CAMH, one of the world's most well-regarded mental health research institutions. Supporting Dr. Gerretsen and Dr. Graff's research by donating PEX010 advances Filament's mission to see safe, natural psychedelics into the hands of everyone who needs them, as soon as possible."

Filament has developed technology that creates pharmaceutical-grade drug candidates from natural compounds, thereby creating valuable IP while increasing speed to market.

Filament’s platform of proprietary technology enables the discovery, development, and delivery of natural psychedelic medicines for clinical development.

The company is committed to furthering psychedelic research globally and has developed licensing partnerships with leading researchers, institutions, and organizations around the world.

Its manufacturing facility has the capacity to supply every psilocybin clinical trial in the world.

The shares are trading at $0.06.

For more information, please visit the company’s website at www.filament.health, contact Anna Cordon, Director of Communications, at 778.245.9067 or by email at anna@filament.health. For investor relations email ir@filament.health.